Definitive Contract 75A50122C00025
Award Date
4/11/22
Potential Completion Date
4/30/23
Potential Value
$703K
Awardee
Lumen Bioscience, Inc.
Ultimate Awardee
Not listed
PSC Category
AN15 - Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major Equipment
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98103, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
50
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Lumen Bioscience, Inc. is for the PANACEA project, an Other Transaction Agreement (OTA) with a ceiling value of $11,137,568.00. The award was made on May 2, 2023 by the Joint PEO Chemical and Biological Defense, a Defense agency, and has an ultimate completion date of December 15, 2024. The contract is focused on providing biological research and development services, including developing biologic drugs and therapeutic delivery platforms. Lumen Bioscience...
This definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Luminex Corporation is valued at $642,450.00. The contract supports the development of Luminex's ARIES SARS-CoV-2 assay under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002. Special Instructions 019 revised the description for mitigating long-term effects of respiratory distress and updated submission deadlines...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a firm fixed-price purchase order contract worth $5,389,813.00 to Luminex Corporation. The contract is for the integration of the SARS-CoV-2 virus with the NxTAG Respiratory Pathogen Panel and the submission of a 510(k) application to the U.S. Food and Drug Administration. Luminex is a manufacturer of biological testing technologies, including multiplex diagnostic solutions,...
This definitive contract awarded by the Department of the Army Medical Command to Luna Innovations Incorporated is a Phase II Small Business Innovation Research project valued at $1.5 million. Under this firm fixed price award, Luna Innovations will conduct medical research and development efforts relating to a COVID-19 vaccine utilizing a layer-by-layer delivery of multiple antigens. The work will be performed in Roanoke, Virginia through September 2023. The solicitation sought proposals to...
The U.S. Defense Health Agency awarded a $2,234,650 fixed-price level of effort contract to Inhalon Biopharma, Inc., a biopharmaceutical company focused on developing inhaled monoclonal antibody therapies for respiratory infections. The contract (ID HT942524C0076) is for developing IN-007, an inhaled treatment that utilizes human ACE2 to target and neutralize various pathogens. The work, which will be performed at Inhalon's facilities in Morrisville, North Carolina, involves activities such as...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency to Luminex Corp, a manufacturer of biological testing technologies. The $1,090.80 award provides an "ANTIBODY COUPLING KIT" to support medical supply chain requirements. The contract has an ultimate completion date of April 18, 2024. Luminex has provided immunology services, laboratory supplies, reagents, multiplexing equipment, and diagnostic testing products to various federal agencies through prime and...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
This is a $9,850,000.00 firm fixed price purchase order awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Luminex Corporation. The contract is to expand the use of Luminex's ARIES SARS-CoV-2 assay, which is a molecular diagnostic test for COVID-19. This award was not set aside for any specific business type. Luminex is a manufacturer of biological testing technologies, including multiplex diagnostic solutions,...
This is a $5,240,000.00 firm fixed price definitive contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Lumiradx, Inc., a foreign-owned, for-profit organization. The contract is for Lumiradx to provide a SARS-CoV-2 & Flu A/B high sensitivity antigen assay under the RADX Tech program. The contract has an ultimate completion date of May 31, 2022 and was awarded on September 30, 2021. This contract is not associated with any set-aside designation.
This is a $74,968.00 firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Luminex Corporation, a foreign-owned, for-profit manufacturer of biological testing technologies. The contract is for the delivery of diagnostic products and services, with a period of performance through April 30, 2026. Luminex holds several significant federal contract vehicles, including a $250,000 single-award indefinite delivery contract (IDC) with the U.S. Department of Agriculture (USDA)...